Stockreport

Blueprint Medicines: Rampant Growth Mostly Priced In [Seeking Alpha]

Blueprint Medicines Corporation  (BPMC) 
Last blueprint medicines corporation earnings: 2/13 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: blueprintmedicines.com
PDF AYVAKIT has been approved for multiple indications, including gastrointestinal stromal tumor and systemic mastocytosis. Blueprint reported strong Q1 2024 earnings, ac [Read more]